Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
ANI Pharmaceuticals Inc (ANIP)  
$67.25 0.14 (0.21%) as of 4:30 Fri 5/3


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 20,430,000
Market Cap: 1.37(B)
Last Volume: 2,387,520 Avg Vol: 2,380,888
52 Week Range: $38.04 - $69.69
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    AMEX COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 254,921 421,551 1,262,027 1,480,093
Total Sell Value $16,747,919 $26,516,522 $74,515,877 $82,888,946
Total People Sold 8 9 12 12
Total Sell Transactions 23 40 87 90
End Date 2024-03-07 2023-12-05 2023-06-06 2022-06-06

   
Records found: 722
  Page 2 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Carey Stephen P. SVP & CFO   •       –      –    2024-04-10 4 D $66.96 $303,597 D/D (4,534) 166,968     -
   Gassert Chad SVP - CORP. DEV. & STRATEGY   •       –      –    2024-04-01 4 AS $67.25 $1,345,000 I/I (20,000) 253,226     -
   Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS   •       –      –    2024-03-28 3 IO $0.00 $0 D/D 0 34,036     -
   Lalwani Nikhil PRESIDENT & CEO   •       •      –    2024-03-23 4 D $69.58 $1,214,519 D/D (17,455) 394,174     -
   Carey Stephen P. SVP & CFO   •       –      –    2024-03-23 4 D $69.58 $432,092 D/D (6,210) 171,502     -
   Marken James G. SVP OPS & PROD DEV   •       –      –    2024-03-23 4 D $69.58 $254,176 D/D (3,653) 118,805     -
   Cook Meredith SR. VP, GENERAL COUNSEL & SEC.   •       –      –    2024-03-13 4 AS $66.54 $16,635 D/D (250) 59,981     -
   Gassert Chad SVP - CORP. DEV. & STRATEGY   •       –      –    2024-03-11 4 AS $65.81 $1,316,200 I/I (20,000) 273,226     -
   Carey Stephen P. SVP & CFO   •       –      –    2024-03-11 4 S $65.55 $510,438 D/D (7,787) 177,712     -
   Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS   •       •      –    2024-03-08 4 AS $67.17 $671,700 I/I (10,000) 832,620     -
   Lalwani Nikhil PRESIDENT & CEO   •       •      –    2024-03-08 4 S $67.13 $1,093,682 D/D (16,292) 411,629     -
   Carey Stephen P. SVP & CFO   •       –      –    2024-03-07 4 D $66.71 $281,249 D/D (4,216) 185,499     -
   Lalwani Nikhil PRESIDENT & CEO   •       •      –    2024-03-07 4 D $66.71 $1,138,073 D/D (17,060) 427,921     -
   Gutwerg Ori SVP, GENERICS   •       –      –    2024-03-07 4 D $66.71 $166,375 D/D (2,494) 80,212     -
   Marken James G. SVP OPS & PROD DEV   •       –      –    2024-03-07 4 D $66.71 $135,688 D/D (2,034) 122,458     -
   Marken James G. SVP OPS & PROD DEV   •       –      –    2024-03-07 4 S $66.37 $1,615,313 D/D (24,338) 124,492     -
   Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS   •       •      –    2024-03-07 4 AS $66.35 $1,000,890 I/I (15,085) 842,620     -
   Mutz Christopher HEAD OF RARE DISEASE   •       –      –    2024-03-07 4 D $66.71 $140,758 D/D (2,110) 85,277     -
   Lalwani Nikhil PRESIDENT & CEO   •       •      –    2024-03-06 4 S $65.52 $1,897,787 D/D (28,965) 444,981     -
   Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS   •       •      –    2024-03-06 4 AS $65.47 $970,396 I/I (14,822) 857,705     -
   Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS   •       •      –    2024-03-05 4 AS $65.35 $659,578 I/I (10,093) 872,527     -
   Mutz Christopher HEAD OF RARE DISEASE   •       –      –    2024-03-05 4 S $66.00 $330,000 D/D (5,000) 87,387     -
   Pera Antonio R Director   –       •      –    2024-03-04 4 S $65.20 $456,400 D/D (7,000) 26,627     -
   Davis Krista SVP, CHIEF HR OFFICER   •       –      –    2024-02-29 4 D $67.67 $79,377 D/D (1,173) 51,545     -
   Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS   •       •      –    2024-02-29 4 D $67.67 $75,926 D/D (1,122) 68,652     -
  722 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 2 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us